buyWeak
Mark J Foley bought $209k of RVNC
CEO at Revance Therapeutics, Inc.. 30,000 shares at an average of $6.98, traded Mar 6, 2024, filed Mar 8, 2024.
Conviction score
37Value
$209k
30,000 shares
Holdings after
1,015,468
+3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +12Trade size$209k at market
- 0Relative to holdingsHoldings up 3.0%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001479290-24-000056, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2024 | POpen-market purchase Common Stock | +30,000 | $6.98 | $209k | 1,015,468 | Mar 8, 2024 |
Related signals
Other insiders at Revance Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | RVNCsell Revance Therapeutics, Inc. | David Hollander CMO & Global Therapeutics Lead | $16k 3,908 shares | -4% | |
| 15Weak | RVNCsell Revance Therapeutics, Inc. | Erica Jordan Chief Commercial Officer | $9,096 2,392 shares | -2% | |
| 36Weak | Revance Therapeutics, Inc. | Dwight Moxie CLO & GC | $41k 8,125 shares | -6% | |
| 43Moderate | Revance Therapeutics, Inc. | Tobin Schilke CFO | $47k 9,361 shares | -5% | |
| 41Moderate | Revance Therapeutics, Inc. | Dustin S Sjuts President | $46k 9,211 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.